Covered recipient · General Payments record
ADELBA L TORRES-LOPEZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$26,603.25
212 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,120.00 | 4 |
| Food and Beverage | $4,983.63 | 199 |
| Consulting Fee | $3,213.00 | 2 |
| Travel and Lodging | $2,286.62 | 7 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 4 of 5; records 151–200 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ADELBA L TORRES-LOPEZ
NPI 1063826543 · CMS profile ID 564234
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SAN JUAN, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1063826543?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063826543?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063826543?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ADELBA L TORRES-LOPEZ, NPI 1063826543, CMS profile ID 564234, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063826543?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
212 matching records · $26,603.25 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 212.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $18.04 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114221524 | CMS |
| Astellas Pharma US Inc | $20.83 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139325100 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.08 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105817375 | CMS |
| SpringWorks Therapeutics, Inc. | $18.24 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1085808639 | CMS |
| Janssen Pharmaceuticals, Inc | $19.61 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078170735 | CMS |
| PBG PUERTO RICO LLC | $20.06 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131205477 | CMS |
| PBG PUERTO RICO LLC | $22.64 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131306091 | CMS |
| ABBVIE INC. | $18.46 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106234032 | CMS |
| Janssen Pharmaceuticals, Inc | $19.26 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078172017 | CMS |
| Bayer Puerto Rico Inc. | $22.00 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086128724 | CMS |
| GENZYME CORPORATION | $18.45 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139864084 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.45 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150197936 | CMS |
| Tempus AI, Inc | $24.71 | 03/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175910 | CMS |
| Eli Lilly Export S.A. Puerto Rico Branch | $20.00 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136008059 | CMS |
| Novartis Pharmaceuticals Corporation | $24.99 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087390702 | CMS |
| SOBI, INC | $24.31 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141418378 | CMS |
| BeiGene USA, Inc. | $22.45 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120860919 | CMS |
| ABBVIE INC. | $25.00 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106234030 | CMS |
| GENZYME CORPORATION | $15.93 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139864050 | CMS |
| Janssen Pharmaceuticals, Inc | $21.18 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078171155 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $15.28 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113858699 | CMS |
| Boston Scientific Corporation | $15.99 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155778353 | CMS |
| Exelixis Inc. | $19.36 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138554290 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.45 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399041 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,638.00 | 02/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399069 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,575.00 | 02/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399211 | CMS |
| Merck Sharp & Dohme LLC | $17.35 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141829312 | CMS |
| Alexion Pharmaceuticals, Inc. | $35.00 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093965433 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.58 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399039 | CMS |
| PBG PUERTO RICO LLC | $16.84 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131189409 | CMS |
| Tempus AI, Inc | $22.09 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175908 | CMS |
| ABBVIE INC. | $19.20 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106234028 | CMS |
| Genentech USA, Inc. | $21.94 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132972393 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.86 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399037 | CMS |
| ADC Therapeutics America, Inc. | $620.00 | 02/06/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121187218 | CMS |
| Amgen Inc. | $19.58 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117400428 | CMS |
| Genmab U.S., Inc. | $16.05 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126823756 | CMS |
| Janssen Pharmaceuticals, Inc | $22.95 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078171117 | CMS |
| Amgen Inc. | $20.80 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117400424 | CMS |
| Merck Sharp & Dohme LLC | $20.86 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141578188 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.95 | 01/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399035 | CMS |
| E.R. Squibb & Sons, L.L.C. | $36.94 | 01/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399217 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.20 | 01/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399219 | CMS |
| Janssen Pharmaceuticals, Inc | $22.45 | 01/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078171305 | CMS |
| Tempus AI, Inc | $100.22 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175906 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.95 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101399029 | CMS |
| Eisai Inc. | $23.83 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110726707 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.80 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105327681 | CMS |
| Exelixis Inc. | $16.15 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138554292 | CMS |
| Rigel Pharmaceuticals, Inc. | $24.33 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145201732 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,278,642.84 | 139 |
| PY2024 | Recipient | $1,537.93 | 9 |
| PY2024 | Principal investigator | $422,074.10 | 42 |
| PY2023 | Recipient | $3,237.20 | 2 |
| PY2023 | Principal investigator | $94,851.88 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
139 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $360.00 | 12/31/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202404651 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $15,228.00 | 12/16/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) | No dispute reported | 06/30/2026 | 1250209181 |
| Principal investigator 1 | BeOne Medicines Ltd. | $750.00 | 12/09/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330863 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 12/08/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330151 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 12/08/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330153 |
| Principal investigator 1 | ABBVIE INC. | $7,718.10 | 12/04/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404643 |
| Principal investigator 1 | ABBVIE INC. | $7,567.30 | 12/04/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404647 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 12/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404640 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $750.00 | 12/03/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1236001775 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 11/25/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 11/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399628 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 11/20/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404627 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 11/20/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404632 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 11/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | No dispute reported | 06/30/2026 | 1211540394 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 11/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | No dispute reported | 06/30/2026 | 1211540398 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 11/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | No dispute reported | 06/30/2026 | 1211540402 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 11/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | No dispute reported | 06/30/2026 | 1211540406 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 11/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len | No dispute reported | 06/30/2026 | 1211540411 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 11/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175399617 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 11/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175399662 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 11/05/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330175 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 11/05/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330177 |
| Principal investigator 1 | ABBVIE INC. | $4,035.20 | 11/04/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404609 |
| Principal investigator 1 | ABBVIE INC. | $7,718.10 | 11/04/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404612 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $650.00 | 11/03/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226120473 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $650.00 | 11/03/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226120477 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $650.00 | 11/03/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226120482 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,750.00 | 10/28/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190332836 |
| Principal investigator 1 | BeOne Medicines Ltd. | $50,304.00 | 10/22/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330441 |
| Principal investigator 1 | Genentech, Inc. | $28,025.00 | 10/20/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211540415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 10/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 10/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399634 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 10/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399642 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/09/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404590 |
| Principal investigator 1 | ABBVIE INC. | $10,487.10 | 10/09/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404595 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/09/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404599 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/09/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404602 |
| Principal investigator 1 | ABBVIE INC. | $18,722.60 | 10/09/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404606 |
| Principal investigator 1 | Genentech, Inc. | $3,500.00 | 10/09/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211540418 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 10/09/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211540421 |
| Principal investigator 1 | Genentech, Inc. | $750.00 | 10/09/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211540426 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/07/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404583 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,857.00 | 10/07/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190333857 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404567 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404571 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404575 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 10/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404580 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 09/17/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336904 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 09/17/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336907 |
| Principal investigator 1 | ABBVIE INC. | $23,667.80 | 09/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404548 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,850.00 | 09/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190338189 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $7,020.00 | 08/19/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190333849 |
| Principal investigator 1 | ABBVIE INC. | $8,944.00 | 08/05/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404536 |
| Principal investigator 1 | ABBVIE INC. | $10,835.50 | 08/05/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404540 |
| Principal investigator 1 | BeOne Medicines Ltd. | $50,304.00 | 07/30/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330463 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 07/29/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336949 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,850.00 | 07/22/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190338185 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $6,786.00 | 07/22/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190333853 |
| Principal investigator 1 | BeOne Medicines Ltd. | $17,250.00 | 07/15/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190330861 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $13,750.00 | 07/15/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190332833 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 07/09/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190337351 |
| Principal investigator 1 | ABBVIE INC. | $16,039.40 | 07/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404524 |
| Principal investigator 1 | ABBVIE INC. | $13,757.90 | 07/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404529 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,818.56 | 06/30/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342251 |
| Principal investigator 1 | BeOne Medicines Ltd. | $14,092.80 | 06/30/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342254 |
| Principal investigator 1 | BeOne Medicines Ltd. | $719.91 | 06/23/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342289 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,879.62 | 06/23/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342292 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175399623 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $2,263.00 | 06/17/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190338832 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 06/16/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337016 |
| Principal investigator 1 | BeOne Medicines Ltd. | $939.52 | 06/16/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337021 |
| Principal investigator 1 | Genmab A/S | $3,500.00 | 06/11/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235921647 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,241.00 | 06/04/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 | No dispute reported | 06/30/2026 | 1185549651 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,697.60 | 06/04/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342368 |
| Principal investigator 1 | ABBVIE INC. | $15,075.00 | 06/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404513 |
| Principal investigator 1 | ABBVIE INC. | $3,789.50 | 06/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404517 |
| Principal investigator 1 | ABBVIE INC. | $17,299.10 | 06/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404521 |
| Principal investigator 1 | BeOne Medicines Ltd. | $50,304.00 | 06/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190330427 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,850.00 | 05/30/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190326140 |
| Principal investigator 1 | ABBVIE INC. | $3,500.00 | 05/29/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202404505 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,439.81 | 05/28/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336767 |
| Principal investigator 1 | BeOne Medicines Ltd. | $9,395.20 | 05/28/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336770 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 05/27/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190337269 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,500.00 | 05/23/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399650 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/15/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404486 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/15/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404497 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 05/15/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404501 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/14/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404473 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/14/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404477 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 05/14/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404480 |
| Principal investigator 1 | BeiGene, Ltd. | $2,000.00 | 05/13/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190325098 |
| Principal investigator 1 | BeiGene, Ltd. | $33,536.00 | 05/08/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190325764 |
| Principal investigator 1 | Eli Lilly and Company | $19,050.00 | 05/07/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) | No dispute reported | 06/30/2026 | 1187873689 |
| Principal investigator 1 | ABBVIE INC. | $19,578.00 | 05/06/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404465 |
| Principal investigator 1 | BeiGene, Ltd. | $9,395.20 | 05/05/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323576 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $5,149.30 | 05/02/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) | No dispute reported | 06/30/2026 | 1250209293 |
| Principal investigator 1 | BeiGene, Ltd. | $2,000.00 | 04/29/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325674 |
| Principal investigator 1 | BeiGene, Ltd. | $750.00 | 04/29/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325676 |
| Principal investigator 1 | BeiGene, Ltd. | $36,371.00 | 04/22/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322456 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 04/16/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321940 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 04/16/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323794 |
| Principal investigator 1 | BeiGene, Ltd. | $5,637.12 | 04/14/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321950 |
| Principal investigator 1 | BeiGene, Ltd. | $14,092.80 | 04/14/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321952 |
| Principal investigator 1 | BeiGene, Ltd. | $2,879.62 | 04/14/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321954 |
| Principal investigator 1 | ABBVIE INC. | $31,268.90 | 04/03/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404457 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 04/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321988 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 04/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321990 |
| Principal investigator 1 | BeiGene, Ltd. | $8,612.72 | 04/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321992 |
| Principal investigator 1 | BeiGene, Ltd. | $1,879.04 | 04/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321994 |
| Principal investigator 1 | BeiGene, Ltd. | $4,697.60 | 04/02/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321996 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,305.35 | 03/19/2025 | Non-covered Recipient Entity Auxilio Mutuo Cancer Center | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235998810 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,000.00 | 03/19/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions | No dispute reported | 06/30/2026 | 1236001773 |
| Principal investigator 1 | BeiGene, Ltd. | $750.00 | 03/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 1190320362 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 03/13/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404451 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 03/10/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322000 |
| Principal investigator 1 | BeiGene, Ltd. | $4,319.43 | 03/10/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322002 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 03/10/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322004 |
| Principal investigator 1 | BeiGene, Ltd. | $7,516.16 | 03/10/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322006 |
| Principal investigator 1 | BeiGene, Ltd. | $14,092.80 | 03/10/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322008 |
| Principal investigator 1 | ABBVIE INC. | $40,844.70 | 03/07/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404447 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 03/05/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322162 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 02/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 02/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity | No dispute reported | 06/30/2026 | 1175399673 |
| Principal investigator 1 | BeiGene USA, Inc. | $2,000.00 | 02/20/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190320364 |
| Principal investigator 1 | BeiGene USA, Inc. | $750.00 | 02/20/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190320368 |
| Principal investigator 1 | AstraZeneca UK Limited | $22,750.00 | 02/18/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) | No dispute reported | 06/30/2026 | 1185549649 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,500.00 | 02/12/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185549647 |
| Principal investigator 1 | BeiGene, Ltd. | $750.00 | 02/11/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325672 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $2,000.00 | 02/10/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) | No dispute reported | 06/30/2026 | 1250209141 |
| Principal investigator 1 | ADC THERAPEUTICS AMERICA, INC. | $750.00 | 02/10/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | STUDY TO EVALUATE LONCASTUXIMAB TESIRINE WITH RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (LOTIS 5) | No dispute reported | 06/30/2026 | 1250209143 |
| Principal investigator 1 | ABBVIE INC. | $4,869.80 | 02/06/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404416 |
| Principal investigator 1 | ABBVIE INC. | $41,012.40 | 02/06/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404421 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 01/29/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202404413 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 01/28/2025 | Covered Recipient Teaching Hospital AUXILIO MUTUO HOSPITAL | M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) | No dispute reported | 06/30/2026 | 1202404409 |
| Principal investigator 1 | BeiGene, Ltd. | $22,167.00 | 01/28/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322454 |
| Principal investigator 1 | BeiGene USA, Inc. | $750.00 | 01/21/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190320366 |
| Principal investigator 1 | Celgene Corporation | $10,000.00 | 01/03/2025 | Covered Recipient Teaching Hospital Auxilio Mutuo Hospital | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial | No dispute reported | 06/30/2026 | 1222305033 |